A Study to Evaluate the Efficacy and Safety of HBM9161 on Moderate to Severe Thyroid Eye Disease

NCT05015127 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Ophthalmopathy

Interventions

DRUG: HBM9161 680 mg qw by q2w from week 13
DRUG: Placebo
DRUG: HBM9161 680 mg qw by q2w from week 7
DRUG: Placebo

Sponsor

Harbour BioMed (Guangzhou) Co. Ltd.